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Abstract
Background—Prolonged pathogen shedding and increased duration of illness associated with 
infections in immunosuppressed individuals put close human immunodeficiency virus (HIV)–
negative contacts of HIV-infected persons at increased risk of exposure to infectious pathogens.
Methods—We calculated incidence and longitudinal prevalence (number of days per year) of 
influenzalike illness (ILI), diarrhea, and nonspecific febrile illness during 2008 from a population-
based surveillance program in the urban slum of Kibera (Kenya) that included 1830 HIV-negative 
household contacts of HIV-infected individuals and 13 677 individuals living in exclusively HIV-
negative households.
Results—For individuals ≥5 years old, incidence was significantly increased for ILI (risk ratio 
[RR], 1.47; P < .05) and diarrhea (RR, 1.41; P < .05) in HIV-negative household contacts of HIV-
infected individuals compared with exclusively HIV-negative households. The risk of illness 
among HIV-negative persons was directly proportional to the number of HIV-infected persons 
living in the home for ILI (RR, 1.39; P < .05) and diarrhea (RR, 1.36; P < .01). We found no 
increased rates of illness in children <5 years old who lived with HIV-infected individuals.
Conclusions—Living with HIV-infected individuals is associated with modestly increased rates 
of respiratory and diarrheal infections in HIV-negative individuals >5 years old. Targeted 
interventions are needed, including ensuring that HIV-infected persons are receiving appropriate 
care and treatment.
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During a variety of bacterial, viral, and parasitic infections, human immunodeficiency virus 
(HIV)–infected patients seem to shed pathogens, in some cases, for longer durations [1–3] 
and in larger numbers than presumably nonimmunosuppressed HIV-negative patients [4]. 
The duration of illnesses may also be longer for HIV-infected patients than for HIV-negative 
patients, as has been shown for influenza [5]. By increasing the infectious period of illnesses 
and the dose and duration of pathogens shed, the risk of transmission to close contacts may 
be increased.
We analyzed data from population-based surveillance conducted by the Kenya Medical 
Research Institute (KEMRI) and the Centers for Disease Control and Prevention (CDC) for 
infectious disease syndromes and their causes and noninfectious conditions in Kibera, an 
urban slum in Nairobi, Kenya [6]. In 2008, home-based HIV-testing and counseling were 
offered to residents of the surveillance area [7], and HIV test results were linked to data 
from infectious disease surveillance of consenting adults. We examined rates of influenza-
like illness (ILI), diarrhea, nonspecific febrile illness, and the noninfectious condition of 
burn injuries in HIV-negative household members living in households with HIV-infected 
individuals compared with those living in households without HIV-infected individuals.
METHODS
Surveillance Site
KEMRI/CDC has conducted population-based, infectious disease surveillance (PBIDS) 
since 2006, in the villages of Gatwikira and Soweto West in Kibera, a slum in Nairobi, 
Kenya. Population ranges between 25 000 and 29 000 persons within a surveillance area of 
0.37 km2 (mean population density, 77 000 persons per square kilometer). The site 
comprises semipermanent houses and shops with communal pit latrines in a mazelike 
arrangement with dirt paths and open sewers. HIV seroprevalence among adults living 
within the surveillance area is 14% [7].
Household and Clinic Surveillance
The ongoing PBIDS program has been described elsewhere [6]. Briefly, all participating 
households are located within 1 km from the study clinic, known as Tabitha Clinic (operated 
by Carolina for Kibera). Persons who have resided within the surveillance area for ≥4 
calendar months are invited to enroll in the study. Participants who consistently share a 
common “cooking pot” are defined as members of the same household. Members of each 
household are assigned a unique identification number and agree to household interviews 
every 2 weeks, conducted by community interviewers. At each reporting round, participants 
are asked standard questions about recent occurrences of illnesses, including fever, diarrhea, 
and respiratory illness, with follow-up questions about severity, length of illness, and type of 
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care sought. Burn injuries occurring within the last 2 weeks, representing a noninfectious 
comparison outcome, are also documented but without follow-up questions. For adults and 
older children not available at the time of interview and for children <5 years old, a proxy 
knowledgeable about the participant's health is interviewed. All surveillance participants 
have access to free care for acute medical conditions at the study clinic.
Written informed consent was obtained for data collection at the clinics and households; for 
minors, consent was obtained from a parent or guardian. The protocol and consent forms 
were reviewed and approved by the Ethical Review Boards of KEMRI (protocol 932) and 
the Institutional Review Board of the CDC (protocol 4566).
Home-Based HIV Testing and Counseling
From 1 January to 31 December 2008, residents of the surveillance area were offered rapid 
HIV tests through home-based testing and counseling (HBTC). All individuals aged ≥18 
years old and emancipated minors (aged 13–17 years) enrolled in PBIDS were given the 
option to consent and participate. Dependent minors were offered HIV tests but required 
parental consent and independent assent. Children (aged ≤13 years) were only offered 
testing if their biological mothers were HIV positive or were deceased. The acceptance rate 
among guardians of these children was very high (96%). Overall, 82.8% of all those eligible 
accepted testing. Informed consent was required to participate in HBTC and to allow data 
from HBTC to be linked to PBIDS data. Procedures, including counseling and follow-up 
testing, have been described elsewhere [7].
Inclusion/Exclusion Criteria for Analysis
If a household had ≥1 resident who had HIV tests processed and results were exclusively 
negative, all individuals in the household were considered to be living in an exclusively 
HIV-negative household. For a household with ≥1 person testing positive for HIV-infection, 
all household members except for the HIV-infected individual (the index case) were 
considered to be household contacts of an HIV-infected individual.
All individuals who tested negative for HIV and children <13 years old who were not tested 
were included in the analysis. Untested individuals ≥13 years old were excluded from the 
analysis owing to the risk of exposure to HIV by sexual transmission. In addition, in 
households with an HIV-infected member, untested children <2 years old were excluded 
because we did not have data to determine the relationship of each member of the household 
to one another (eg, biological mother, father, or child) and thus were unable to rule out 
vertical transmission of HIV. Given that mortality for untreated HIV-infected infants in sub-
Saharan Africa is substantial by age 2 years [8], we assumed that untested children surviving 
past this age were HIV negative and had minimal risk of acquisition until age 13 years; thus, 
we categorized children 2–13 years old, who were not tested, as not HIV infected.
Case Definitions
Case definitions were fulfilled based on data collected from the fortnightly household visits. 
A case of ILI was defined as reported fever or “hotness of body” with either cough or sore 
throat. Diarrhea was defined as ≥3 stools that were looser than normal or ≥1 episode of 
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blood in stools during a 24-hour period; discrete cases of diarrheal illness were preceded by 
≥3 symptom-free days. Nonspecific febrile illness was defined as any report during the 
household visit of fever (“hotness of body”) within the previous 2 weeks without evidence 
of another infection defined as cough, difficulty breathing, ILI, or diarrhea. A symptom-free 
period of ≥7 days was used to define discrete cases for both ILI and febrile illness. A burn 
injury was defined as any report of a burn during the study period with ≥14 days of no 
previous report of a burn.
Analysis
The study period for incidence and longitudinal prevalence of these conditions was 1 
January to 31 December 2008. Incidence rates were calculated as the number of discrete 
episodes of an illness over the total person-years of observation (PYO) and reported in units 
of episodes per PYO. Based on previous analyses of data from PBIDS suggesting significant 
decay in recall for events occurring more than a few days before the interview [9], we 
counted only symptoms of illnesses reported to be occurring on the day of visit and during 
the 3 previous days (days 0–3) for children aged <5 years and the 4 previous days (days 0–4) 
for persons aged ≥5 years. There was no recall limit for burn injuries because the specific 
date of injury within that reporting round is not asked.
The denominators (reported in PYO for incidence calculations) were adjusted according to 
the boundaries of the recall limit. For home visit rounds during which the HIV-infected 
index case patient was reported as migrated out of or not present within the surveillance 
area, the illness data and respective PYO for all members of the household were excluded 
from the analysis. We also excluded PYO for reporting rounds during which an interview 
was not conducted. For identifying symptom-free days to define discrete episodes, we used 
the entire reporting period without recall bias restrictions.
We modeled incidence and longitudinal prevalence of illnesses at the household level using 
Poisson regression (PROC GENMOD; SAS version 9.1; SAS Institute) in 2 different cohort 
methods. First, we compared HIV-negative individuals living with only HIV-negative 
household members with those living with ≥1 HIV-infected household member. We then 
compared individuals living in exclusively HIV-negative households with HIV-negative 
individuals living with 1, 2, or ≥3 HIV-infected household members, modeled as a 
continuous variable, to determine a dose-dependent relationship. We controlled for intra-
household correlation using generalized estimating equations and controlled for household 
size as a covariate in the analysis. We assumed the “independent” correlation matrix 
structure in these analyses.
RESULTS
During the study period, 27 821 persons and 6858 households were enrolled in PBIDS. HIV 
tests were performed in 7427 individuals residing in 4064 households. There were 3466 
households with exclusively HIV-negative residents. The mean household size was 6.3 
persons (95% confidence interval [CI], 6.2–6.4). These households included 6608 untested 
individuals ≥13 years old (52% of all persons ≥13 years old in these households), who were 
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excluded from analysis (Table 1). A total of 6704 HIV-negative individuals (≥13 years old) 
and 6973 untested children <13 years old (total of 13 677) were included in the analysis.
There were 598 households with ≥1 person who tested HIV positive. The mean household 
size was 7.1 persons (95% CI, 6.8–7.4), significantly larger than households with 
exclusively HIV-negative residents. These households included 723 individuals testing 
positive for HIV; 1264 untested adults ≥13 years old (representing 64% of all persons ≥13 
years old in these households), and 264 untested children ≤2 years old were excluded from 
the analysis. A total of 473 HIV-negative individuals and 1357 untested children <13 years 
old (and >2 years old) were included in the analysis (Figure 1).
Influenzalike Illness
Among persons aged ≥5 years, there were 0.19 cases of ILI (95% CI, .12–.34) and 0.81 days 
(95% CI, .43–1.51) of ILI per PYO for household contacts of ≥1 HIV-infected individual 
compared with 0.13 cases (95% CI, .08–.21) and 0.52 days (95% CI, .31–.88) of ILI per 
PYO for persons living in exclusively HIV-negative households. This represents a 
statistically significant 1.51-fold higher incidence and a 1.55-fold greater longitudinal 
prevalence. When results were stratified by the number of HIV-infected individuals, there 
was a significant 1.44-fold increase and a 1.53-fold increase in longitudinal prevalence for 
individuals ≥5 years old with each additional HIV-infected household member. No 
significant differences were seen for children <5 years old (Table 2; Figure 2A).
Diarrheal Illness
Among persons ≥5 years old living with ≥1 HIV-infected individual, there were 0.31 cases 
(95% CI, .21–.44) and 0.84 days (95% CI, .56–1.24) of diarrheal illness per PYO compared 
with 0.22 cases (95% CI, .17–.27) and 0.56 days (95% CI, .43–.72) per PYO for individuals 
living in exclusively HIV-negative households. This was a statistically significant 1.42-fold 
increase in incidence and a 1.49-fold increase in longitudinal prevalence per PYO. In the 
analysis stratified by number of HIV-infected individuals, the incidence of diarrhea was 
significantly increased by 1.38-fold and longitudinal prevalence by 1.44-fold for each 
additional HIV-infected individual in the household. No significant differences were found 
for children <5 years old (Table 3; Figure 2B).
Nonspecific Febrile Illness
For persons ≥5 years old, there were statistically significant increases of 1.15-fold (95% CI, 
1.02–1.29) in incidence and 1.17-fold (95% CI, 1.02–1.35) in longitudinal prevalence for 
each additional HIV-infected individual in the household in the analysis stratified by number 
of HIV-infected individuals; however, there was no significant increase in incidence or 
longitudinal prevalence in the non-stratified analysis (Table 4; Figure 2C). For children <5 
years old living with ≥1 HIV-infected individual, there were 4.00 cases (95% CI, 3.36–4.77) 
of nonspecific febrile illness per PYO compared with 4.71 cases (95% CI, 4.18–5.30) for 
those living in exclusively HIV-negative households, a significant 0.85-fold decrease in 
incidence. However, this was an isolated finding for children <5 years old, because there 
were no significant differences in longitudinal prevalence in this nonstratified analysis or in 
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incidence and longitudinal prevalence for the analysis stratified by number of HIV-infected 
individuals.
Burn Injuries
Burn injuries, a significant noninfectious problem within the surveillance area [10], was 
included in this analysis to detect analytic bias, because HIV-infected household members 
would not be expected to contribute to risk in HIV-negative residents. For individuals ≥5 
and <5 years old, there were no significant increases in burn incidence or prevalence. The 
analysis stratified by number of HIV-infected household members also failed to find an 
association between household HIV status and burn injury incidence in either age category 
(Table 5; Figure 2D).
DISCUSSION
The findings of these analyses of population-based data in an urban slum in Nairobi suggest 
that living with HIV-infected persons may be one of many community and environmental 
components that increase rates of acute respiratory and diarrheal illnesses for HIV-negative 
individuals ≥5 years old. Evidence of increased rates of infections with each additional HIV-
infected individual living in the household suggests that the effect is dose dependent. In 
contrast to the infectious syndromes analyzed, the incidence of noninfectious condition 
(burn injury) was not significantly elevated in HIV-negative household contacts of HIV-
infected individuals. We have not identified any other studies that have systematically 
compared the incidence of acute infections in immunocompetent individuals living within 
the context of an HIV-infected household member(s). However, studies on the health of 
HIV-negative household members living with HIV-infected individuals receiving 
cotrimoxazole prophylaxis showed a significant reduction in overall mortality and morbidity 
after prophylaxis was started, implying that failure to prevent infections in HIV-infected 
individuals has a measurable impact on the health of close contacts [11]. Our results add 
further evidence that HIV may be a risk factor for transmission of diarrheal and respiratory 
illness that could amount to considerable extra disease burden across a large population.
A biological basis for the observed increased transmission of diarrheal and respiratory 
illness is built on evidence for increased incidence and prolonged shedding of pathogens in 
HIV-infected hosts. During Cryptosporidium outbreaks, HIV-infected individuals have been 
shown to shed greater numbers of oocysts and have diarrhea for a longer duration than HIV-
negative individuals, and immunocompromised individuals may have chronic transmissible 
cryptosporidiosis for months [12]. Respiratory pathogens (eg, influenza) in the 
immunocompromised host can also result in longer periods of shedding and longer durations 
of illness [13–16]. Kibera is a densely populated and impoverished urban slum with 
inadequate sanitation, poor air quality, and lack of access to clean water. Given these 
features that increase the efficiency of transmission of respiratory and orofecal infections, 
small increases in duration of pathogen shedding due to HIV-infection could translate into 
higher disease incidence.
Although our analysis showed increased rates of infectious syndromes in individuals ≥5 
years old living with HIV-infected persons, the same analysis for children <5 years old did 
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not show a similar association. One possibility is that children <5 years old, who are 
immunologically naive to many pathogens, experience high incidence of acute diarrheal and 
respiratory infections; given the wide variety of pathogen exposure opportunities in an urban 
slum, additional pathogen exposure in the household may not add measurably to increased 
risk of illness [17, 18]. Given substantial environmental exposure to respiratory and 
diarrheal pathogens for young children, another consideration is that children <5 years old 
might tend to be the index case in the household [19–22]. Household-reported rates of ILI in 
our surveillance, for instance, are >8-fold greater for children 1–2 years old than for adults 
18–34 years old (6.6 vs 0.87 cases per PYO) [23]. The increased exposure of children <5 
years old to diarrheal and respiratory pathogens from HIV-infected individuals ≥5 years old 
would therefore not be expected to significantly increase rates of illness as we found in our 
model of adult-to-adult transmission.
Our analysis of nonspecific febrile illness did not follow the same clear pattern of increased 
rates of illness in individuals ≥5 years old that we observed for diarrheal and respiratory 
illnesses. We found an isolated, significant decrease in febrile illness incidence (but not 
longitudinal prevalence) for children <5 years old living with HIV -infected persons that was 
not found when results were stratified by number of HIV-infected persons, and a significant 
increase in incidence and longitudinal prevalence in individuals ≥5 years old only when 
results were stratified by number of HIV-infected individuals. There is a wide variety of 
causes of febrile illness in Africa, including vector-borne diseases, such as malaria, 
rickettsiosis, dengue, and Chikungunya, as well as other environmentally linked diseases, 
such as leptospirosis or typhoid fever, that would probably not be affected by household 
exposure to an HIV-infected individual [24, 25]. It is also possible that there was a change in 
the epidemiology of a specific, direct-contact viral or bacterial pathogen owing to behavior 
modification after the diagnosis of an HIV infection that could have influenced the incidence 
of this syndrome. Overall, these results suggest that further investigations into the causes of 
nonspecific febrile illness in this study population are needed to explain these findings.
Interventions to improve the health of HIV-infected populations in areas of resource-limited 
settings and high HIV prevalence should be evaluated in future studies for evidence of 
parallel reduction in a variety of infectious syndromes among HIV-negative household 
members. Highly active antiretroviral therapy has greatly reduced morbidity and the 
incidence of infections among HIV-infected individuals in sub-Saharan Africa, and the 
World Health Organization has recently updated its recommendation for initiation of 
treatment at much higher CD4 cell counts than in previous guidelines [26–28]. The 
implementation of these new guidelines, as well as other interventions aggressively 
promoting highly active antiretroviral therapy to manage or prevent HIV infection could 
have substantial impact on community-level health. Moreover, water quality and hand 
washing interventions focused on HIV-infected populations and urban slum populations 
have individually shown dramatic reductions in diarrheal illness in their respective target 
groups and should also be evaluated for their additive effects in preventing diarrhea in HIV-
infected individuals and their household contacts living in urban slums like Kibera [29–31]. 
Although the effectiveness of pneumococcal and influenza vaccines in HIV-infected persons 
is well documented, the effect of community transmission dynamics for these pathogens in a 
population with high HIV prevalence warrants further investigation [32, 33].
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Because a substantial proportion (64%) of adults in households determined to be exclusively 
HIV negative were untested, it is likely that some HIV-positive households were 
misclassified. However, such misclassification would have biased toward the null (ie, 
households incorrectly classified as HIV negative would have been subject to more 
opportunistic infections, diminishing the calculated risk ratios); thus, it is conceivable that 
the effects we observed represented underestimates. Moreover, data on the progression of 
HIV infection that could modify the effect we were measuring, such as longitudinal CD4 
cell counts, viral load, or cotrimoxazole and antiretroviral use, were unavailable for analysis.
In 2008–2009, HBTC was rapidly increasing access to HIV care, which could have 
decreased our rates of household transmission. However, as with the previous limitation, 
omission of these variables would have biased results toward the null, further 
underestimating the true morbidity of untreated HIV-infection in our analysis. Follow-up 
studies assessing the effects of aggressive HIV treatment or antibiotic prophylaxis in this 
population would elucidate the potentially protective effects of chronic disease management 
in the epidemiology of acute infections. The only potential misclassification that would not 
bias toward the null was our inability to be certain that persons testing negative for HIV 
remained uninfected throughout the observation period, especially individuals living with 
HIV-infected household members, among whom there might be a higher incidence of HIV 
infection. To minimize this effect, we restricted the observation period to a single year after 
the completion of HBTC, not only to limit the cumulative incidence of seroconversion in the 
group but also, in the event of seroconversion, to exclude the period of profound, chronic 
immunosuppression occurring later in disease progression, which we assume is the main 
driver of increased rates of infections in household with HIV-infected individuals.
Households with ≥1 individual who tested HIV positive were significantly larger in number 
than households with exclusively HIV-negative residents, introducing the possibility that 
increased rates of infectious illness were due to increased opportunities for exposure to ill 
persons (HIV infected or not) in the household. However, after controlling for household 
size in our analysis, we demonstrated that for all significant differences found in our 
analyses, the presence of an HIV-infected person in the household was an independent risk 
factor for illness occurring in non–HIV-infected members of household and that this 
independent risk increases with the number of HIV-infected persons in the household.
Reporting bias could also have been introduced by a household proxy either overreporting or 
underreporting the illness of a household member based on their knowledge of that 
member's HIV status. Furthermore, a lack data on household socioeconomic features limited 
our ability to address potential confounders in our study population, such as economic 
hardship, stigma, or caregiver fatigue, which are associated with overall poorer health 
outcomes and could preferentially affect households living with an HIV-infected member 
[34–36].
Our findings provide an initial step for quantifying increased transmission of acute 
infectious pathogens among HIV-negative individuals when ≥1 member of the household is 
HIV infected. This is a “proof of concept” that should inform further studies and 
interventions aimed at disease prevention in this unique and expanding milieu of poverty, 
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high HIV prevalence, and poor sanitation. Characterizing the community-wide benefits of 
maintaining the health of HIV-infected individuals and preventing new HIV infections could 
have major implications for the 35 million HIV-infected individuals, their family members, 
and potentially other persons within communities with high HIV prevalence.
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Figure 1. 
Number of human immunodeficiency virus (HIV)–negative individuals included in each 
comparison group (exclusively HIV-negative households vs households with ≥1 HIV-
infected member).
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Figure 2. 
Incidence of acute illnesses for persons ≥5 years old, stratified by number of human 
immunodeficiency virus (HIV)–infected household members. Abbreviations: ILI, 
influenzalike illness; PYO, person-years of observation.
Wong et al. Page 13
J Infect Dis. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Wong et al. Page 14
Table 1
Percentage of Adults Tested for HIV in Households Included in the Analysisa
HIV-Infected Household Contacts, No. Households, No. Adults in Household Not Tested, %
0 3466 52
1 484 63
2 104 65
3 10 66
Total 4064 53
Abbreviation: HIV, human immunodeficiency virus.
aAdults were defined as persons ≥13 years old.
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